Press Releases published on December 23, 2020
As the end of this year draws near, we at The Lynx Group would like to take this opportunity to thank all of you for an amazing 2020. We also share a celebration of our victories and accomplishments with everyone, while reflecting on ways to improve as we progress into the new year! The success of The Lynx Group is based on the effective and vibrant relationships we have forged over the years; we simply wouldn’t be where we are without you. We are extremely grateful for the opportunity to work with, and for you!
Journal of Hematology Oncology Pharmacy Named Official Publication of the Hematology/Oncology Pharmacy Association
Press Releases published on March 16, 2020
The Lynx Group, a global strategic alliance of medical communications and education companies, is pleased to announce that its Journal of Hematology Oncology Pharmacy™ (JHOP) has been named the official publication of the Hematology/Oncology Pharmacy Association (HOPA).
IMBRUVICA™ Approved For Previously Treated Chronic Lymphocytic Leukemia; Immediately Available Through Onco360®
Mekinist™ (trametinib) & Tafinlar® (dabrafenib) Approved In Combination; Both Limited Distribution Products Immediately Available Via Onco360®
PharMerica and Onco360 Finalize Strategic Investment; Establish First National Oncology Pharmacy and Care Management Platform
Results 1 - 6 of 6